68Ga-NI-FAPI is named as a drug or biological intervention in 2 clinical trials in our China trial register, 2 of which are recruiting. Lead sponsors include First Affiliated Hospital of Fujian Medical University (1) and Peking Union Medical College Hospital (1). Registered phases: Phase EARLY_PHASE1 and Phase 1/2. Conditions studied include Malignant Neoplasm; Tumor; Cardiovascular Diseases.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06688305 | 68Ga-NI-FAPI PET/CT: First-in-human Study Malignant Neoplasm |
Phase EARLY_PHASE1 | Recruiting |
| NCT07464132 | Application of [68Ga]Ga-NI-FAPI-04 PET/CT Imaging in Fibroblast Activation Protein Related Diseases (ClinicalTrials.gov ↗) Tumor, Cardiovascular Diseases, Pulmonary Fibrosis |
Phase 1/2 | Recruiting |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Malignant Neoplasm | 1 |
| Tumor | 1 |
| Cardiovascular Diseases | 1 |
| Pulmonary Fibrosis | 1 |
| Rheumatic Immune Diseases Involving Large Blood Vessels | 1 |
| Lead sponsor | Trials |
|---|---|
| First Affiliated Hospital of Fujian Medical University | 1 |
| Peking Union Medical College Hospital | 1 |
| Register | 68Ga-NI-FAPI trials |
|---|---|
| Clinical trials in China | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how 68Ga-NI-FAPI works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists 68Ga-NI-FAPI (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.